Icagen breathes freely as Phase IIa asthma trial enthuses investors
This article was originally published in Scrip
Executive Summary
Icagen's potassium channel antagonist, senicapoc, failed to produce statistically significant differences to placebo in a Phase IIa allergic asthma trial, but still sent share prices soaring by almost 50%, to close at $1.43 on Nasdaq on September 1st after data were released. Share prices have since stabilised at around $1.25.